Highlights

  • Cochlear sold 56,692 implants in FY26, increasing units by 5% across its global hearing solutions business.
  • Services Revenue grew 6% to AUD 635 million, reflecting upgrades and support for existing recipients.
  • The Nucleus Nexa System accounted for more than 95% of developed-market implant sales after launch.
  • Management forecast FY27 underlying net profit of AUD 330–350 million with a focus on operating costs.

A new generation of implant technology is entering Cochlear’s financial outlook after a year of uneven regional demand. Cochlear Limited (ASX:COH) grew unit sales in FY26 while reporting lower Underlying Profit and a narrower gross margin. Its Nucleus Nexa rollout, recurring services and FY27 operating targets now provide the principal milestones for tracking the hearing technology group.

Product Lines and Implant Volumes

Cochlear designs and sells implantable hearing solutions, including cochlear implants, bone conduction implants and acoustic devices, and supports recipients through sound processors, upgrades and services. Revenue falls into three main groups.

Cochlear implants brought in $1,435 million, about 61% of sales, and were flat in constant currency. Services, which include sound processor upgrades and support for existing recipients, contributed $635 million and grew 6%. Acoustics added $273 million, around 12% of sales, up 1%.

Implant units reached 56,692, an increase of 5%. Unit growth running ahead of revenue growth points to a higher share of lower-priced products, which the company linked to its emerging-market mix.

Regional Sales and Margin Performance

The regional picture was uneven. In constant currency, cochlear implant sales rose 4% in the United States and 7% in Asia Pacific, but fell 8% in Western Europe and 2% in emerging markets. Services in developed markets grew 13%.

Gross margin slipped from 74% to 71%, which the company attributed to sales mix and production variances. Reported operating expenses were $1,251 million, up 5%, although comparable operating expenses fell 1% once restructuring costs were excluded. Research and Development spending rose 15% to $323 million, or about 14% of sales.

That combination is the heart of the Earnings squeeze. Cochlear kept investing in technology while gross margin fell, so profit declined faster than revenue.

Cash Generation and Nucleus Nexa

Cash flow was a brighter spot. Operating Cash Flow was $368 million, about $130 million higher than in FY25, and free cash flow of roughly $263.5 million was more than double the prior year.

Net cash was $188 million, slightly below the company's preferred level of about $200 million, so the on-market share buyback remained inactive.

The final ordinary Dividend was $1.30 per share, 85% franked, bringing the FY26 total to $3.45 per share, a 20% decline. Cochlear targets a payout of about 70% of underlying net profit, so dividends follow earnings.

The Nucleus Nexa System is the first smart cochlear implant with upgradeable firmware. Cochlear said it accounted for more than 95% of implant sales in developed markets, a fast transition that suggests clinicians and patients have accepted it.

FY27 Guidance and Operating Priorities

For FY27, management guided to low single-digit constant-currency revenue growth and underlying net profit of $330 million to $350 million. Gross margin is expected to be 70% to 71%, research and development about 13% of sales, and operating expenses to decline slightly.

A cloud technology programme is expected to cost about $60 million after tax and be reported as a significant item. Restructuring costs, which sit outside comparable expenses, are expected to fall away in FY27 according to the investor presentation coverage reviewed. Reported commentary also indicated a stronger Australian dollar would weigh on translated earnings, since most of Cochlear's sales are made in foreign currencies, though the size of that effect should be checked against the company's own documents.